Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
NICE recommended golimumab (in combination with methotrexate) for adults with severe active rheumatoid arthritis who have already tried other DMARDs, including a TNF inhibitor, only if they cannot take rituximab therapy for medical reasons or because they had a bad reaction to it. This is because treatment with golimumab costs more than treatment with rituximab.